AllQuantitative Report
logoArgusApril 21, 2021

RGNX: Lowering target price to $35.00

Symbols
RGNX
Sector(s)
Healthcare
Rating
Current Price
$36.27
Price Target
$NaN
Earnings Estimate
Summary

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free